Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05308212
Other study ID # FLM-TE-04-2020
Secondary ID
Status Completed
Phase Phase 2/Phase 3
First received
Last updated
Start date March 4, 2021
Est. completion date September 6, 2021

Study information

Verified date March 2022
Source St. Petersburg Research Institute of Vaccines and Sera
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Comparative assessment of the tolerability, safety, and immunogenicity of the FLU-M® Tetra quadrivalent inactivated split influenza vaccine and the Ultrix® vaccine in volunteers aged 60 years and above.


Description:

Evaluation of the tolerability, safety and immunogenicity of the inactivated split influenza vaccine FLU-M® Tetra compared to Ultrix® vaccine in volunteers aged 60 years and above. Volunteers were screened and randomized in three groups: the Flu-M Tetra w/p (with preservative) group, the Flu-M Tetra w/o/p (without preservative) group and the Ultrix® group. All subjects were followed up for 28 days post randomization and vaccination.


Recruitment information / eligibility

Status Completed
Enrollment 633
Est. completion date September 6, 2021
Est. primary completion date July 30, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 60 Years and older
Eligibility Inclusion Criteria: 1. Volunteers (men and women) at the age of 60 years and above 2. Written informed consent of volunteers to participate in the clinical trial; 3. Volunteers able to fulfill requirements of the Protocol (i.e. fill out the patient's diary, come to follow-up visits); 4. For fertile women - a negative result of the pregnancy test and consent to observe adequate methods of contraception during the trial and at least two months after vaccination; 5. For fertile men - consent to observe adequate methods of contraception during the trial and at least two months after vaccination, except for men after vasectomy with documented azoospermia, and their sexual partners should use methods of contraception that ensure more than 90% reliability or be incapable of conception after a surgical sterilization or have a natural menopause for at least 2 years. Exclusion Criteria: 1. History of influenza/ARVI or previous influenza vaccination during 6 months before the trial; 2. Positive result of the SARS-CoV-2 test; 3. A serious post-vaccination reaction (temperature above 40 °C, hyperemia or edema more than 8 cm in diameter) or complications (collapse or shock-like condition that developed within 48 hours after vaccination; convulsions accompanied or not accompanied by a fever due to any previous vaccination); 4. Allergic reactions to vaccine components or any previous vaccination; 5. History of allergic reaction to chicken protein; 6. History of Guillain-Barré syndrome (acute polyneuropathy); 7. Previous vaccination with rabies vaccines less than 2 months before immunization or scheduled vaccination with rabies vaccines within 1 month after immunization with the trial vaccines; 8. History of leukemia, cancer, autoimmune diseases; 9. Positive blood test results for HIV, syphilis, hepatitis B/C. 10. Volunteers who received immunoglobulin or blood products or had a blood transfusion during the last three months before the trial; 11. History of long-term use (more than 14 days) of immunosuppressants or immunomodulatory drugs for six months before the trial; 12. History of any confirmed or suspected immunosuppressive or immunodeficiency condition; 13. History of chronic diseases of the cardiovascular, bronchopulmonary, neuroendocrine systems, the gastrointestinal tract, liver, kidneys, hematopoietic, immune and endocrine system, mental disease in the acute stage or in the decompensation stage (recovery less than 4 weeks before vaccination); 14. History of eczema; 15. Treatment with glucocorticosteroids, including in small doses, as well as local use of drugs containing steroids (> 10 mg of prednisolone or its equivalent for more than 14 days before the screening); 16. Tuberculosis, neurological or mental disorders, a convulsive syndrome, including in the past medical history; 17. History of acute infectious diseases (recovery less than 4 weeks before vaccination); 18. Consumption of more than 10 units of alcohol per week or history of alcohol addiction, drug addiction or abuse of pharmaceutical products; 19. Smoking of more than 10 cigarettes per day; 20. Participation in another clinical trial during the last 3 months; 21. Pregnancy or lactation; 22. Coagulopathy, haemophilia; 23. Taking aspirin or other antiplatelet agents in high doses.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Flu-M Tetra [Inactivated split influenza vaccine] w/p
solution for intramuscular injection, 0.5 ml
Flu-M Tetra [Inactivated split influenza vaccine] w/o/p
solution for intramuscular injection, 0.5 ml
Ultrix [Inactivated split influenza vaccine]
solution for intramuscular injection, 0.5 ml

Locations

Country Name City State
Russian Federation State Autonomous Health Institution "Engels City Clinical Hospital No1" Engels
Russian Federation Limited Liability Company Professorskaya Clinica Perm
Russian Federation Limited Liability Company Energia Zdorovya Saint Petersburg
Russian Federation Limited Liability Company MEDICINSKAYA CLINIKA Saint Petersburg
Russian Federation Limited Liability Company Scientific Research Center Eco-Bezopasnost Saint Petersburg
Russian Federation Piramida Limited Liability Company Saint Petersburg
Russian Federation Private Health Care Institution Clinical Hospital "RZD-Medicine" in Saint Petersburg Saint Petersburg
Russian Federation Saint Petersburg State Budgetary Healthcare Institution "State Polyclinic No. 117" Saint Petersburg
Russian Federation Saint Petersburg State Budgetary Healthcare Institution "State Polyclinic No. 43" Saint Petersburg
Russian Federation Limited Liability Company "DNA Research Center" Saratov
Russian Federation Federal State Budget Healthcare Institution "Yaroslavl Region Clinical Hospital No. 2" Yaroslavl

Sponsors (1)

Lead Sponsor Collaborator
St. Petersburg Research Institute of Vaccines and Sera

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary Geometric mean titer (GMT) ratio of antibodies after vaccination Geometric mean titer (GMT) of antibodies in the blood serums of vaccinated people in haemagglutination inhibition assay. days 0, 28
Secondary Change from baseline seroconversion rate at 28 days Seroconversion rate refers to the percentage of subjects who have a prevaccination titer of influenza haemagglutinin antibody titer (HA titer) = 1:10 and a post-vaccination HA titer = 1:40 or a prevaccination HA titer > 1:10 and at least a 4-fold increase in post-vaccination HA titer vs. the baseline. days 0, 28
Secondary Seroconversion factor Seroconversion factor is an increase in the geometric mean titers of antibodies at Day 28 vs. the baseline level, expressed in the fold rise. days 0, 28
Secondary Seroprotection rate Seroprotection rate refers to the percentage of subjects with a generated protective HA titer (at least 1:40) vs. the baseline level. days 0, 28
Secondary Frequency of development of AEs associated with the vaccination An adverse event (AE) is any adverse medical occurrence in a trial subject who has received a pharmaceutical product or medicine that does not necessarily have a causal relationship with the medicine.
AE include: new disease, complication of signs or symptoms of the condition being treated or a concomitant disease, effect of the trial drug or the reference drug, effect associated with a trial procedure, any combination of one or more of these factors.
days 0-28
Secondary Frequency of development of SAEs associated with the vaccination An adverse event is considered serious if it is fatal, threatens the life, requires hospitalization or extension of hospitalization, results in permanent or significant disability, is a congenital abnormality or defect (not applicable to this trial), is an important medical event. days 0-28
Secondary Number of participants with abnormal physical examination findings Physical examination of volunteers includes an interview, discovery of complaints and symptoms, when required, palpation, auscultation, percussion for the following organs and systems: skin, mucosa, eyes, oral cavity and pharynx, lungs/chest, cardiovascular system, abdominal organs, nervous system, lymph nodes, musculoskeletal system, endocrine system. days 0,1,3,7,28
Secondary Results of assessment of blood pressure (BP) BP measurements include the systolic and diastolic blood pressure. days 0,1,3,7,28
Secondary Results of assessment of heart rate (HR) HR is measured during auscultation of the heart in parallel with determining the pulse rate on the radial artery (or on the carotid artery in case of weak pulsation in the radial artery) for a minute while sitting. days 0,1,3,7,28
Secondary Results of E immunoglobulin tests Determination of total IgE. days 0,3,28
Secondary Results of assessment of respiratory rate (RR) RR is measured for a minute at rest in the sitting position, by registering the breathing movements of the chest or abdominal wall, without attracting the patient's attention. days 0,1,3,7,28
Secondary Results of assessment of body temperature Body temperature is measured with a mercury or digital thermometer in the armpit for at least 5 minutes or with a non-contact infrared digital thermometer. days 0,1,3,7,28
Secondary Number of participants with abnormal neurological examinations Assessement of neurological status, cranial nerve function, motor sphere, reflex sphere, sensitive sphere, coordination sphere, pelvic functions, higher mental functions. days 0,1,3,7,28
Secondary Number of participants with abnormal ECG findings ECG QT Interval, QTc Interval, PQ Interval, QRS complex. days 0,3
Secondary Number of participants with abnormal complete blood counts results Hemoglobin, hematocrit, erythrocytes, leukocytes, platelets, leukocyte count, ESR. days 0,3
Secondary Number of participants with abnormal biochemical blood tests results Total protein, creatinine, urea, glucose, total bilirubin, total cholesterol, AST, ALT, ALP. days 0,3
Secondary Number of participants with abnormal urinalysis results pH, specific gravity, protein, glucose, red blood cells, white blood cells days 0,3
See also
  Status Clinical Trial Phase
Completed NCT05523089 - The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults Phase 2
Completed NCT05009251 - Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake N/A
Completed NCT03282240 - Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US Phase 3
Completed NCT00971425 - Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1) Phase 3
Completed NCT00968526 - Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults Phase 3
Completed NCT00968539 - Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults Phase 3
Completed NCT05525494 - Patient Portal Flu Vaccine Reminders (5) N/A
Completed NCT04074928 - Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects Phase 3
Completed NCT04695717 - This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam Phase 3
Completed NCT05012163 - Lottery Incentive Nudges to Increase Influenza Vaccinations N/A
Completed NCT04109222 - Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively Phase 4
Completed NCT03888989 - Response to Influenza Vaccine During Pregnancy Phase 1
Completed NCT02587221 - Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age Phase 3
Completed NCT03453801 - The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection Phase 1
Completed NCT01440387 - A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older Phase 3
Terminated NCT01195779 - Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children Phase 2
Completed NCT03321968 - Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults Phase 3
Completed NCT00972517 - Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children Phase 3
Completed NCT04570904 - Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
Recruiting NCT03331991 - Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel N/A